GIANT BIOGENE (02367) announced that its wholly-owned subsidiary, Shaanxi Giant Biogene Technology Co., Ltd., has received a Medical Device Registration Certificate (Registration Certificate No.: 国械注准20263130044) from the National Medical Products Administration (NMPA) for its recombinant Type I α1 collagen and sodium hyaluronate compound solution product.

This product, which uses recombinant collagen and sodium hyaluronate as its primary components, is intended for injection into the dermis to improve cheek smoothness.

It is the world's first recombinant collagen and sodium hyaluronate compound solution implant approved through a combined device and pharmaceutical review process for improving cheek smoothness.

Following the successful approval of the recombinant Type I α1 collagen lyophilized fiber, this new product further expands the company's product portfolio, showcasing the group's sustained leadership in technological R&D and industrial capabilities.

The approval also unlocks broader market potential, injecting new growth momentum into the company's business development in the skin rejuvenation field.

Moving forward, the company will steadily advance the market launch and promotion of this product, aiming to provide differentiated solutions for diverse consumer needs through its multi-product portfolio, comprehensive channel network, and sophisticated brand management.

These efforts will continue to strengthen the company's leading market position in the health and beauty sectors.